Baseline symptom burden and dual bronchodilator response in the FLAME study
A. Mackay (London, United Kingdom), K. Kostikas (Basel, Switzerland), S. Frent (Timisoara, Romania), P. Olsson (Täby, Sweden), P. Pfister (Basel, Switzerland), P. Gupta (Hyderabad, India), F. Patalano (Basel, Switzerland), D. Banerji (East Hanover, United States of America), J. Wedzicha (London, United Kingdom)
Source: International Congress 2018 – COPD management
Session: COPD management
Session type: Thematic Poster
Number: 4387
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Mackay (London, United Kingdom), K. Kostikas (Basel, Switzerland), S. Frent (Timisoara, Romania), P. Olsson (Täby, Sweden), P. Pfister (Basel, Switzerland), P. Gupta (Hyderabad, India), F. Patalano (Basel, Switzerland), D. Banerji (East Hanover, United States of America), J. Wedzicha (London, United Kingdom). Baseline symptom burden and dual bronchodilator response in the FLAME study. 4387
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Dual bronchodilator response according to bronchitis symptoms in the FLAME study Source: International Congress 2018 – COPD management Year: 2018
Evaluating acute bronchodilator response with subjective and objective criteria in stable COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 64s Year: 2005
Health status changes in COPD patients after real-life switch from tiotropium or salmeterol/fluticasone to indacaterol/glycopyrronium using the EQ-5D-3L instrument: results from the POWER study Source: International Congress 2018 – COPD management Year: 2018
COPD exacerbations significantly impact quality of life as measured by SGRQ-C total score: results from the FLAME study Source: International Congress 2017 – Novel mechanisms and treatments for COPD Year: 2017
Triple therapy de-escalation to dual bronchodilation in COPD patients: Baseline data from the DACCORD cohort Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
Value of measuring SGRQ at stable phase of COPD to predict the timing and deterioration associated with next exacerbation: the MOSAIC study Source: Eur Respir J 2004; 24: Suppl. 48, 240s Year: 2004
Baseline exhaled NO in relation to asthma control improvement after increased dose of inhaled steroids – A real-life study Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013
The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma Source: International Congress 2017 – Bronchial asthma management Year: 2017
The usefulness of a combination with patient-based questionnaire and lung function test for predicting asthma exacerbation Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches Year: 2009
Improving COPD symptoms with umeclidinium/vilanterol and impact of baseline disease severity: the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Short-term recovery in SGRQ following a COPD exacerbation in the MOSAIC study correlates with the preceding deterioration, but is larger Source: Eur Respir J 2004; 24: Suppl. 48, 686s Year: 2004
A comparison between the diagnostic value of bronchodilator response in spirometry and questionnaire in determining asthma Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms Year: 2012
Short-term HRQL deterioration during early-phase COPD exacerbation: a prospective Canadian cohort study Source: Eur Respir J 2005; 26: Suppl. 49, 296s Year: 2005
Asthma control and COPD symptom burden: results from a multi-country observational study (SPRINT) in patients using fixed dose combination (FDC) inhalers Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018
Reproducibility and patient acceptability of the inhaled corticosteroid questionnaire (ICQ): a patient self-reported side effect scale Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
Early changes in eDiary COPD symptoms predict trough FEV1 and TDI responders at 12 weeks in the CRYSTAL trial Source: International Congress 2017 – Management of COPD Year: 2017
Evaluation of the individual bronchodilator response in patients with severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002
Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021
Impact of asthmatic patient satisfaction with the inhaler upon adherence, disease control and quality of life. Results of the ASCONA study Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Clinical utility of impulse oscillation system (IOS) for the assessment of clinical status and therapeutic efficacy in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 421s Year: 2006